Frost & Sullivan: Life Sciences Organizations Cannot Afford to Miss the "Next Big Thing"

Frost & Sullivan: Life Sciences Organizations Cannot Afford to Miss the "Next Big Thing" PR Newswire MOUNTAIN VIEW, California, Dec. 18, 2012 - Companies must look cross-vertically to capitalize on emerging markets, trends and growth opportunities MOUNTAIN VIEW, California, Dec. 18, 2012 /PRNewswire/ -- The top global pharmaceutical companies are employing new growth strategies to counter mounting industry challenges like patent expiration of several blockbuster drugs, as well as fewer drug approvals. Frost & Sullivan's latest analysis explores three new growth strategies: renewed focus on complex diseases that are difficult to treat, open innovation programs to accelerate drug discovery, and entry into emerging markets in which healthcare spending is growing. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) Global Life Sciences Trends and Opportunities research finds that the industry consists of several billion dollar markets totaling $1.35 trillion in 2012, which is anticipated to reach $5.01 trillion in 2015. This global life sciences analysis discusses three technologies with "bench to bedside" potential, including next-generation sequencing, microRNA and digital polymerase chain reaction (PCR). If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.